Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Industry ponders reimbursement crisis

Article Abstract:

Biotechnology executives attending workshops at the Biotechnology Industry Organization's discussed on the potential impact of future healthcare reimbursement strategies on the profitability of biotechnology products. Industry observers are concerned that reforms of the US healthcare reimbursement system could have damaging repercussions for biopharmaceutical manufacturers by eliminating potential markets.

Author: Bouchie, Aaron
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
Health Care and Social Assistance, Management dynamics, Services information, Drugs, HEALTH SERVICES, Health Care Services, Medical & Health Services, Management, Biotechnology industry, Biotechnology industries, Services, Medical care, Company business management, Medical care (Private)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


McClellan moves on, sets sights on drug reimbursement

Article Abstract:

The appointment of Mark McClellan as the new administrator for the Centers for Medicare and Medicaid Services (CMS), which is responsible for providing healthcare facilities for the poor, disabled and patients above the age of sixty-five has been confirmed by the United States (US) senate. Revamping the CMS and the issues related to drug reimbursement will act as the major challenges for Mark McClellan.

Author: Bouchie, Aaron
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Executive changes & profiles, Officials and employees, Appointments, resignations and dismissals, McClellan, Mark

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


New rules for US drug reimbursement

Article Abstract:

Two proposed rules for drug reimbursement are released by the US centers for Medicare and Medicaid services. Biotech companies are concerned for the 'part B' drugs, the bulk of which are injectable biologics and cancer therapeutics.

Author: Bouchie, Aaron
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
Medicaid, Powers and duties

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Laws, regulations and rules, Government regulation, Prospective payment systems (Medical care), United States. Centers for Medicare and Medicaid Services
Similar abstracts:
  • Abstracts: Voluntary disclosure of management earnings forecasts in IPO prospectuses. Discussion of Voluntary disclosure of management earnings forecasts in IPO prospectuses
  • Abstracts: McCain mulls regulation of costs, more competition in DOD buys
  • Abstracts: 50% car lease deduction under threat. Making a clean breast of it. We can work it out
  • Abstracts: Current developments. Partnership provisions of the American Jobs Creation Act of 2004. Litigation developments in the partnership and LLC tax arena
  • Abstracts: Incorporating user satisfaction into the look-and-feel of mobile phone design. Product design, semantics and emotional response
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.